JURA Bio

JURA Bio, Inc. is an AI-native biotechnology company focused on building frontier foundation models for therapeutic design. The company operates at the intersection of artificial intelligence and wet-lab experimentation, creating a self-reinforcing data loop in which its models drive the laboratory experiments that generate the proprietary functional data needed to continuously improve those same models. This closed-loop approach — spanning design, synthesis, and screening — produces functional signal at a scale that no public dataset can match, enabling JURA to tackle novel modalities and hard targets where off-the-shelf AI solutions fall short.

JURA Bio serves biopharmaceutical researchers, drug discovery organizations, and strategic partners seeking AI-driven solutions for early-stage therapeutic development. The company has attracted significant press attention and has established collaborations across biologics development, gene regulation, and cell therapy.

Core Platform Capabilities

• Sovereign AI Models: Purpose-built foundation models trained exclusively on proprietary functional data, designed for novel modalities and difficult targets where public data is absent and general-purpose AI tools are insufficient. These models improve iteratively with every experimental cycle, compounding their predictive power over time.
• AI Data Loop: JURA's platform integrates AI model outputs directly with wet-lab workflows, enabling large-scale de novo design and ensuring that each round of experimentation feeds back into model training — creating a continuously expanding proprietary data asset.
• Removal of Synthesis Bottlenecks: The platform is designed to address and eliminate traditional DNA synthesis bottlenecks that slow drug discovery and development pipelines.

Therapeutic Modalities and Candidate Discovery

• JURA's platform supports the discovery and development of therapeutic candidates with confirmed biological function across a broad range of modalities.
• Supported modalities include antibodies, TCR mimics, peptides, T-cell engagers, enzymes, and other emerging therapeutic formats.
• Candidates are discovered and developed end-to-end by JURA's sovereign AI systems, with functional validation built into the discovery process.

Strategic Partnerships and Collaborations

• JURA x Koa Bio: A collaboration focused on rapid biologics development targeting emergent bacterial threats, leveraging JURA's AI-driven design capabilities for fast-response therapeutic development.
• JURA x Annogen: A partnership aimed at powering regulatory element design using sovereign data-trained models, applying JURA's platform to the field of gene regulation.
• JURA & Replay / Syena: A partnership between JURA Bio and Replay's product company Syena to advance T cell receptor NK (natural killer) therapies in oncology, combining JURA's AI platform with Syena's cell therapy expertise.

Recognition and Press Coverage

• JURA was named one of six companies worthy of note in AI drug discovery by Genetic Engineering & Biotechnology News (November 2024).
• The company's AI data loop enabling large-scale de novo antibody design was featured in GEN (July 2025).
• JURA has been covered in major life sciences publications including Endpoints News, Nature Biotechnology, BioInsights, and DayOne Switzerland, as well as featured at industry forums including IO 360.
• The company raised $16 million in seed funding and was co-founded with ties to the George Church laboratory, with a founding vision to bring machine learning to cell therapy.

JURA Bio represents a new paradigm in AI-native drug discovery — one in which the AI system and the laboratory are deeply integrated, each accelerating the other to generate proprietary biological intelligence that compounds in value with every experimental cycle.